Proteon Therapeutics, Inc. (NASDAQ:PRTO) Files An 8-K Other Events
Item 8.01. Other Events.
On June 22, 2017, the Company issued a press release announcing
that Proteon entered into a securities purchase agreement with a
syndicate of current and new institutional investors, led by an
affiliate of Deerfield Management, for the sale of convertible
preferred stock for gross proceeds of $22.0 million. The press
release is attached to this Current Report as Exhibit 99.1 hereto
and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 |
Press Release, dated June 22, 2017, issued by Proteon Therapeutics, Inc. |
PROTEON THERAPEUTICS INC ExhibitEX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Proteon Therapeutics Announces $22.0 Million Private PlacementProvides Sufficient Cash into Q4 2019 WALTHAM,…To view the full exhibit click here About Proteon Therapeutics, Inc. (NASDAQ:PRTO)
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.